Eteplirsen and Duchenne's accelerated approval (2016)
Sarepta Therapeutics sought approval of eteplirsen for Duchenne based on a small study and a surrogate measure of dystrophin production. FDA reviewers objected, and an advisory committee voted 7-6 that the evidence did not support approval.
The FDA granted accelerated approval in September 2016 and required a confirmatory trial.
Accelerated approval kept the drug available while the argument over its evidence continued, and the case became a reference point in debates over how much proof rare-disease drugs need.
It shows the FDA will accept thin evidence in Duchenne when the fight is over how to read the data. Deramiocel's rejection is about whether the data can be believed at all.
